AstraZeneca | Investor Day Presentation Deck | 49 slides · page 19 of 49
The slide uses a Kaplan-Meier survival curve for HSCT-TMA and market sizing metrics for CSA-AKI.
Conference presentation · key_messages · quantify_opportunity · overcrowded density
Slide locked Sign in to view
Slide schematic 8/8
callout 1/1 chart 1/1 metric 2/2 source-note 1/1 table 1/1 title 2/2
Components 8
primary line big-number big-number source-note data headline subtitle
Tools 2
Big Idea Formula slide · 70%
Ultomiris potential to be first-and-only medicine for HSCT-TMA, and first-and-only preventative therapy for CSA-AKI
Storytelling: the three headline reasons slide · 70%Ultomiris indication expansion will continue, Ultomiris potential to be first-and-only medicine for HSCT-TMA, and first-and-only preventative therapy for CSA-AKI
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.